Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.29, Iss.12, 2013-12, pp. : 1617-1626

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucagon‐like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 335-342

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1065-1074

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 468-473

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. S1, 2018-02 ,pp. : 68-76

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of gastric inhibitory polypeptide, glucagon‐like peptide‐1 and glucagon‐like peptide‐1 receptor agonists on Bone Cell Metabolism

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 122, Iss. 1, 2018-01 ,pp. : 25-37

John Wiley & Sons Inc

Access to resources Recommend Favorite